Published in J Neural Transm (Vienna) on September 09, 2008
Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry (2011) 1.27
Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry (2013) 0.88
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. Eur Child Adolesc Psychiatry (2013) 0.84
Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents. Indian J Psychol Med (2016) 0.81
Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatr Dis Treat (2010) 0.80
Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents. Adolesc Health Med Ther (2014) 0.77
Review of the safety of second-generation antipsychotics: are they really "atypically" safe for youth and adults? Prim Care Companion CNS Disord (2012) 0.77
Correlates of weight gain during long-term risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health (2012) 0.77
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents. Eur Child Adolesc Psychiatry (2011) 0.76
Dietary Fructose and GLUT5 Transporter Activity Contribute to Antipsychotic-Induced Weight Gain. Schizophr Bull (2016) 0.75
Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. J Neural Transm (Vienna) (2016) 0.75
Risperidone in children with autism and serious behavioral problems. N Engl J Med (2002) 9.35
Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry (1999) 8.04
Medical hazards of obesity. Ann Intern Med (1993) 3.93
Risperidone in the treatment of schizophrenia. Am J Psychiatry (1994) 3.92
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol (1999) 2.21
Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry (2001) 2.06
Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry (1996) 1.92
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry (2002) 1.75
The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry (2002) 1.68
A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry (2001) 1.61
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry (2002) 1.60
Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry (1998) 1.59
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry (1995) 1.55
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry (1997) 1.54
Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry (1999) 1.53
An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry (1998) 1.43
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology (2004) 1.38
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry (2006) 1.30
A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry (2000) 1.30
Diabetes mellitus in schizophrenic patients. Compr Psychiatry (1996) 1.27
Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry (1999) 1.26
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry (2002) 1.21
Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry (2001) 1.18
Differential effect of clozapine on weight: a controlled study. Am J Psychiatry (1996) 1.10
Dosing the antipsychotic medication olanzapine. J Clin Psychiatry (1997) 1.09
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol (2001) 1.08
Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry (1992) 1.06
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol (2001) 1.06
Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry (1999) 1.01
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol (2000) 0.97
A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry (2003) 0.95
Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis. Pediatr Diabetes (2008) 0.94
Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry (2004) 0.93
Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev (1995) 0.90
Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol (1998) 0.90
Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol (2000) 0.90
Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol (2006) 0.89
Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry (1997) 0.88
Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol (1997) 0.87
Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry (2002) 0.87
Risperidone and explosive aggressive autism. J Autism Dev Disord (1997) 0.86
A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol (2003) 0.86
Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol (2001) 0.86
Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol (2003) 0.84
Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol (1998) 0.84
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm (Vienna) (2006) 0.83
A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol (2002) 0.82
Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol (2000) 0.82
Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol (2003) 0.81
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm (Vienna) (2003) 0.81
Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol (1998) 0.80
Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol (2000) 0.80
Weight gain associated with psychotropic drugs. South Med J (1989) 0.79
An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry (1994) 0.79
Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry (1999) 0.78
[The atypical neuroleptic clozapine (Leponex)--current knowledge and recent clinical aspects]. Fortschr Neurol Psychiatr (1995) 0.78
Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol (1999) 0.78
Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J (1983) 0.78
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol (2008) 0.78
Meta-analysis of genome-wide association studies of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2010) 3.13
Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res (2002) 2.56
Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry (2012) 2.48
Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J Neural Transm (Vienna) (2008) 2.43
Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med (2008) 2.23
Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest (2004) 2.22
Obsessive-compulsive disorder in children and adolescents. Dtsch Arztebl Int (2011) 2.10
Physical inactivity rapidly induces insulin resistance and microvascular dysfunction in healthy volunteers. Arterioscler Thromb Vasc Biol (2007) 2.07
Strong genetic evidence of DCDC2 as a susceptibility gene for dyslexia. Am J Hum Genet (2005) 1.94
Sex differences and the impact of steroid hormones on the developing human brain. Cereb Cortex (2008) 1.90
Case-control genome-wide association study of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2010) 1.86
Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation (2011) 1.76
Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet (2011) 1.63
Development of attentional networks: an fMRI study with children and adults. Neuroimage (2005) 1.62
Impaired induction of long-term potentiation-like plasticity in patients with high-functioning autism and Asperger syndrome. Dev Med Child Neurol (2012) 1.55
Prevalence of mental health problems among children and adolescents in Germany: results of the BELLA study within the National Health Interview and Examination Survey. Eur Child Adolesc Psychiatry (2008) 1.49
Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2008) 1.48
[Increase in incidence of drug treatments, ethical principles and conflict of interest in cooperation with the pharmaceutical industry]. Z Kinder Jugendpsychiatr Psychother (2012) 1.46
Morphometric brain abnormalities in boys with conduct disorder. J Am Acad Child Adolesc Psychiatry (2008) 1.46
Neurophysiological correlates of relatively enhanced local visual search in autistic adolescents. Neuroimage (2007) 1.45
The relationship between premorbid body weight and weight at referral, at discharge and at 1-year follow-up in anorexia nervosa. Eur Child Adolesc Psychiatry (2014) 1.43
Manganese superoxide dismutase and aldehyde dehydrogenase deficiency increase mitochondrial oxidative stress and aggravate age-dependent vascular dysfunction. Cardiovasc Res (2008) 1.43
Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab (2003) 1.40
Dysfunctional attentional networks in children with attention deficit/hyperactivity disorder: evidence from an event-related functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.40
Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention (2014) 1.39
Structural brain abnormalities in adolescents with autism spectrum disorder and patients with attention deficit/hyperactivity disorder. J Child Psychol Psychiatry (2007) 1.36
Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radic Biol Med (2005) 1.36
First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerin-triggered vascular dysfunction. Antioxid Redox Signal (2008) 1.34
A locus on 2p12 containing the co-regulated MRPL19 and C2ORF3 genes is associated to dyslexia. Hum Mol Genet (2007) 1.32
Reward system dysfunction in autism spectrum disorders. Soc Cogn Affect Neurosci (2012) 1.30
Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res (2003) 1.29
Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension (2006) 1.26
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res (2012) 1.24
Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2004) 1.23
Induced delusional disorder. a review of the concept and an unusual case of folie à famille. Psychopathology (2003) 1.23
Empathy in children with autism and conduct disorder: group-specific profiles and developmental aspects. J Child Psychol Psychiatry (2011) 1.23
Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum Mol Genet (2004) 1.20
Growing up is hard: mental disorders in adolescence. Dtsch Arztebl Int (2013) 1.20
Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J Clin Endocrinol Metab (2004) 1.17
Differential effects of social and non-social reward on response inhibition in children and adolescents. Dev Sci (2009) 1.16
Tobacco smoke exposure before, during, and after pregnancy and risk of overweight at age 6. Obesity (Silver Spring) (2011) 1.16
Response to emotional stimuli in boys with conduct disorder. Am J Psychiatry (2005) 1.14
Emotional processing in male adolescents with childhood-onset conduct disorder. J Child Psychol Psychiatry (2008) 1.14
Activation of endothelial nitric-oxide synthase by the p38 MAPK in response to black tea polyphenols. J Biol Chem (2004) 1.13
Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. Eur J Hum Genet (2005) 1.13
Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury. Proc Natl Acad Sci U S A (2004) 1.13
Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord (2010) 1.13
Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder: genome-wide association study of both common and rare variants. Am J Med Genet B Neuropsychiatr Genet (2013) 1.11
High loading of polygenic risk for ADHD in children with comorbid aggression. Am J Psychiatry (2013) 1.10
Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2011) 1.09
ALDH-2 deficiency increases cardiovascular oxidative stress--evidence for indirect antioxidative properties. Biochem Biophys Res Commun (2007) 1.09
Long-term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study. J Am Acad Child Adolesc Psychiatry (2007) 1.09
Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol (2005) 1.08
Atypical brain responses to reward cues in autism as revealed by event-related potentials. J Autism Dev Disord (2011) 1.08
Examining the relationship between attention-deficit/hyperactivity disorder and overweight in children and adolescents. Eur Child Adolesc Psychiatry (2011) 1.08
Genome scan for childhood and adolescent obesity in German families. Pediatrics (2003) 1.08
Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J (2008) 1.08
Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes (2011) 1.07
AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med (2008) 1.07
Neuronal correlates of facial emotion discrimination in early onset schizophrenia. Neuropsychopharmacology (2008) 1.07
Further evidence for DYX1C1 as a susceptibility factor for dyslexia. Psychiatr Genet (2009) 1.06
Long-term outcome and prognosis of dissociative disorder with onset in childhood or adolescence. Child Adolesc Psychiatry Ment Health (2008) 1.04
Attentional dysfunction in children after corrective cardiac surgery in infancy. Ann Thorac Surg (2007) 1.04
Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol (2003) 1.04
Altered response control and anterior cingulate function in attention-deficit/hyperactivity disorder boys. Clin Neurophysiol (2004) 1.04
No evidence for involvement of genetic variants in the X-linked neuroligin genes NLGN3 and NLGN4X in probands with autism spectrum disorder on high functioning level. Am J Med Genet B Neuropsychiatr Genet (2008) 1.02
Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol (2005) 1.02
Ghrelin gene: identification of missense variants and a frameshift mutation in extremely obese children and adolescents and healthy normal weight students. J Clin Endocrinol Metab (2002) 1.02
Health-related quality of life in adolescents and young adults with high functioning autism-spectrum disorder. Psychosoc Med (2010) 1.00
Psychological and psychiatric aspects of pediatric obesity. Child Adolesc Psychiatr Clin N Am (2009) 1.00
Investigation of interaction between DCDC2 and KIAA0319 in a large German dyslexia sample. J Neural Transm (Vienna) (2008) 1.00
Investigation of the DCDC2 intron 2 deletion/compound short tandem repeat polymorphism in a large German dyslexia sample. Psychiatr Genet (2008) 1.00
The extent of social anxiety in combination with mental disorders. Eur Child Adolesc Psychiatry (2006) 0.99
Neural mechanisms of empathy in adolescents with autism spectrum disorder and their fathers. Neuroimage (2009) 0.99
Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal (2013) 0.98
Long-term course of adolescent schizophrenia. Schizophr Bull (2005) 0.97
Theory of mind and the brain in anorexia nervosa: relation to treatment outcome. J Am Acad Child Adolesc Psychiatry (2012) 0.97
Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. Hypertension (2013) 0.97
Coherent motion processing in autism spectrum disorder (ASD): an fMRI study. Neuropsychologia (2010) 0.97
Genetics of early-onset obsessive-compulsive disorder. Eur Child Adolesc Psychiatry (2010) 0.97
A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol (2007) 0.97
Gastric dilatation in a girl with former obesity and atypical anorexia nervosa. Int J Eat Disord (2002) 0.97
Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. J Epidemiol Community Health (2009) 0.96
Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol (2007) 0.96
Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol (2011) 0.96